Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + apatinib + pegaspargase
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Intramuscular
01
Overview
CAPA is an induction immunotherapy combination regimen consisting of the PD-1 inhibitor camrelizumab, the VEGFR-2 tyrosine kinase inhibitor apatinib, and the asparagine-depleting enzyme pegaspargase. It is currently being evaluated in Phase 2 clinical trials (notably NCT04366128) as a first-line treatment for patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma (ENKTL), nasal type. The regimen is designed to provide a synergistic therapeutic effect by combining immune checkpoint blockade, antiangiogenesis, and metabolic depletion of asparagine, potentially offering a more effective and less toxic alternative to traditional intensive chemotherapy regimens for this aggressive lymphoma subtype.
- Other names
- CAPA regimenCAPA induction immunotherapy
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on camrelizumab + apatinib + pegaspargase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + apatinib + pegaspargase.